Literature DB >> 3567059

Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitizes them to the anti-proliferative effects of tamoxifen.

H W van den Berg, W J Leahey, M Lynch, R Clarke, J Nelson.   

Abstract

Exposure of ZR-75-1 human breast cancer cells for 48 h to human recombinant interferon alpha (IFN alpha) resulted in increased expression of oestrogen receptors as measured in a whole cell binding assay. This effect was inversely proportional to dose being significant following treatment with 10-100 IU IFN ml-1 and was only observed at a low initial cell plating density. The extent of the increase in oestrogen receptor levels ranged from 1.2- to 7.2-fold following treatment with 10 IU IFN ml-1. No increase in progesterone receptor expression was observed under the same experimental conditions. Concentrations of IFN which increased oestrogen receptor levels had no effect on cell proliferation. IFN (500 IU ml-1) inhibited cell proliferation and the combination of this treatment with tamoxifen (2 microM) had a greater anti-proliferative effect than either drug alone although there was no evidence of synergism. However, a 5-day pretreatment of cells with IFN (10 IU ml-1) markedly sensitised them to the growth-inhibiting effect of a subsequent 6-day exposure to tamoxifen.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3567059      PMCID: PMC2001764          DOI: 10.1038/bjc.1987.49

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  8 in total

1.  In vitro model systems for the study of hormone-dependent human breast cancer.

Authors:  M E Lippman; C K Osborne; R Knazek; N Young
Journal:  N Engl J Med       Date:  1977-01-20       Impact factor: 91.245

2.  Interferon as a modifier of estrogen receptors.

Authors:  N V Dimitrov; C J Meyer; H Strander; S Einhorn; K Cantell
Journal:  Ann Clin Lab Sci       Date:  1984 Jan-Feb       Impact factor: 1.256

3.  The Woolf plot is more reliable than the Scatchard plot in analysing data from hormone receptor assays.

Authors:  D D Keightley; N A Cressie
Journal:  J Steroid Biochem       Date:  1980-11       Impact factor: 4.292

4.  Assay for estrogen and progesterone receptors of breast cancer cell lines in monolayer culture.

Authors:  N Olea-Serrano; N Devleeschouwer; G Leclercq; J C Heuson
Journal:  Eur J Cancer Clin Oncol       Date:  1985-08

5.  Influence of cell proliferation and cell cycle phase on expression of estrogen receptor in MCF-7 breast cancer cells.

Authors:  R Jakesz; C A Smith; S Aitken; K Huff; W Schuette; S Shackney; M Lippman
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

6.  Recombinant leukocyte A interferon in advanced breast cancer. Results of a phase II efficacy trial.

Authors:  S A Sherwin; D Mayer; J J Ochs; P G Abrams; J A Knost; K A Foon; S Fein; R K Oldham
Journal:  Ann Intern Med       Date:  1983-05       Impact factor: 25.391

7.  Administration of fibroblast interferon to patients with advanced breast cancer: possible effects on skin metastasis and on hormone receptors.

Authors:  P Pouillart; T Palangie; M Jouve; E Garcia-Giralt; W H Fridman; H Magdelenat; E Falcoff; A Billiau
Journal:  Eur J Cancer Clin Oncol       Date:  1982-10

8.  Recombinant interferon in advanced breast cancer.

Authors:  A Nethersell; H Smedley; M Katrak; T Wheeler; K Sikora
Journal:  Br J Cancer       Date:  1984-05       Impact factor: 7.640

  8 in total
  23 in total

1.  IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis.

Authors:  Yanxia Ning; Rebecca B Riggins; Jennifer E Mulla; Haniee Chung; Alan Zwart; Robert Clarke
Journal:  Mol Cancer Ther       Date:  2010-05       Impact factor: 6.261

Review 2.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

3.  Auto-tumor recognition following in vitro induction of MHC antigen expression on solid human tumors: stimulation of lymphocytes and generation of cytotoxicity against the original MHC-antigen-negative tumor cells.

Authors:  F Vánky; G Stuber; S Rotstein; E Klein
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Phenotypic and functional profile of peripheral blood mononuclear cells isolated from melanoma patients undergoing combined immunotherapy and chemotherapy.

Authors:  A Eisenthal; Y Skornick; I Ron; V Zakuth; S Chaitchik
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

5.  Androgen receptors and hormone sensitivity of a human prostatic cancer cell line (PC-3) are modulated by natural beta-interferon.

Authors:  G Sica; G Dell'Acqua; F Iacopino; A Fattorossi; P Marchetti; T H van der Kwast; M Pavone-Macaluso
Journal:  Urol Res       Date:  1994

6.  Tamoxifen enhances interferon-regulated gene expression in breast cancer cells.

Authors:  D J Lindner; V Kolla; D V Kalvakolanu; E C Borden
Journal:  Mol Cell Biochem       Date:  1997-02       Impact factor: 3.396

7.  Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells.

Authors:  Robert Clarke; Ayesha N Shajahan; Rebecca B Riggins; Younsook Cho; Anatasha Crawford; Jianhua Xuan; Yue Wang; Alan Zwart; Ruchi Nehra; Minetta C Liu
Journal:  J Steroid Biochem Mol Biol       Date:  2009-03       Impact factor: 4.292

8.  Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo.

Authors:  R Clarke; N Brünner; B S Katzenellenbogen; E W Thompson; M J Norman; C Koppi; S Paik; M E Lippman; R B Dickson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

9.  Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer.

Authors:  J E Macheledt; A U Buzdar; G N Hortobagyi; D K Frye; J U Gutterman; F A Holmes
Journal:  Breast Cancer Res Treat       Date:  1991-08       Impact factor: 4.872

10.  Human recombinant interferon-beta SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse.

Authors:  D F Gibson; D A Johnson; D Goldstein; S M Langan-Fahey; E C Borden; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.